MRK
Merck & Co., Inc.
Price performance
Sep 18, 2026About
Company activity
19 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 08/04 | MRK | 8-K | Merck Reports Second-Quarter 2026 Financial Results and Key Regulatory Milestones | — | — | — |
| 05/28 | MRK | 8-K | Merck & Co., Inc. Announces Election Results from Annual Meeting of Shareholders | — | — | — |
| 05/22 | MRK | 8-K | Merck & Co., Inc. Issued New Debt Securities | — | — | — |
| 04/30 | MRK | 8-K | Merck Reports First-Quarter 2026 Financial Results and Highlights Regulatory Approvals | — | — | — |
| 02/03 | MRK | 8-K | Merck & Co., Inc. Reports Fourth Quarter and Year-End 2025 Earnings | — | — | — |
| 12/04/25 | MRK | 8-K | Merck & Co., Inc. Announces Issuance of Multiple Series of Notes | — | — | — |
| 10/30/25 | MRK | 8-K | Merck Reports Third Quarter 2025 Earnings | — | — | — |
| 09/09/25 | MRK | 8-K | Merck & Co., Inc. Issued New Notes | — | — | — |
| 07/29/25 | MRK | 8-K | Merck Announces Second-Quarter 2025 Financial Results and New Restructuring Program | — | — | — |
| 05/29/25 | MRK | 8-K | Merck & Co., Inc. Announces Results of Annual Shareholder Meeting | — | — | — |
| 04/24/25 | MRK | 8-K | Merck Reports First-Quarter 2025 Financial Results | — | — | — |
| 02/04/25 | MRK | 8-K | Merck & Co., Inc. Reports 2024 Earnings | — | — | — |
| 11/22/24 | MRK | 8-K | Merck Announces Appointment of New Board Member | — | — | — |
| 10/31/24 | MRK | 8-K | Merck Announces Third-Quarter 2024 Financial Results and Business Updates | — | — | — |
| 07/30/24 | MRK | 8-K | Merck Announces Second-Quarter 2024 Financial Results | — | — | — |
| 05/30/24 | MRK | 8-K | Merck Subsidiary Completes €3.4 Billion Notes Offering | — | — | — |
| 04/25/24 | MRK | 8-K | Merck Reports Strong Q1 2024 Earnings, Raises Outlook | — | — | — |
| 02/20/24 | MRK | 8-K | Peter C. Wendell to Retire from Merck's Board of Directors | — | — | — |
| 02/01/24 | MRK | 8-K | Merck Announces 2024 Restructuring Program and 2023 Earnings | — | — | — |
MRK filing record
Merck & Co., Inc. (MRK): 19 8-K filings summarized, the most recent on Aug 4, 2026.
What the 8-K filings said
- Aug 4, 2026 · high impact
Merck & Co., Inc. reported second-quarter 2026 financial results, showing total worldwide sales of $16.6 billion, a 5% increase year-over-year. The company highlighted strong performance in oncology, with notable sales growth for KEYTRUDA and WINREVAIR. Merck also announced several regulatory approvals, including the…
Merck Reports Second-Quarter 2026 Financial Results and Key Regulatory Milestones - May 28, 2026 · high impact
Merck & Co., Inc. held its Annual Meeting of Shareholders on May 26, 2026. The meeting included the election of the Company's Board of Directors, with all nominees receiving a majority of votes. Shareholders also approved the compensation of named executive officers, ratified the appointment of the independent…
Merck & Co., Inc. Announces Election Results from Annual Meeting of Shareholders - May 22, 2026 · medium impact
On May 22, 2026, Merck & Co., Inc. closed an underwritten public offering of various notes totaling $5.35 billion in aggregate principal amount. The notes have different interest rates and maturity dates ranging from 2028 to 2056.
Merck & Co., Inc. Issued New Debt Securities - Apr 30, 2026 · high impact
Merck & Co., Inc. reported first-quarter 2026 financial results, showing total worldwide sales of $16.3 billion, a 5% increase year-over-year. The company reported a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, primarily due to a $3.62 per share charge for the acquisition of Cidara. Key product…
Merck Reports First-Quarter 2026 Financial Results and Highlights Regulatory Approvals - Feb 3, 2026 · low impact
Merck & Co., Inc. has announced its financial results for the fourth quarter and year-end 2025, as detailed in a press release issued on February 3, 2026. The report includes key financial metrics and performance indicators for the period, providing insights into the company's operational and financial health at the…
Merck & Co., Inc. Reports Fourth Quarter and Year-End 2025 Earnings
SEC filings in the last five years
- 31 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K
- 1 Form 10-K/A